Recherche
Résultats 1-10 de 21
-
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular b-cell lymphoma (galen): a multicentre, single-arm, phase 2 study
The Lancet. Haematology, 08-07-2019Article dans une revue scientifique -
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-hodgkin lymphoma: final results from a phase 2 randomised study (romulus)
The Lancet. Haematology, 29-03-2019Article dans une revue scientifique -
Patient-reported outcomes in keynote-087, a phase 2 study of pembrolizumab in patients with classical hodgkin lymphoma
Leukemia & lymphoma, 23-04-2019, 1-7Article dans une revue scientifique -
On-target pharmacodynamic activity of the pi3k inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors
Molecular cancer therapeutics, 16-10-2019Article dans une revue scientifique -
Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the filo group
British journal of haematology, 22-05-2019Article dans une revue scientifique -
Zr-immuno-pet: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo
Journal of nuclear medicine . official publication, Society of Nuclear Medicine, 30-05-2019Article dans une revue scientifique -
F-fdg-pet dissemination features in diffuse large b cell lymphoma are prognostic of outcome
Journal of nuclear medicine . official publication, Society of Nuclear Medicine, 14-06-2019Article dans une revue scientifique -
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Leukemia, 26-09-2019, 33, 2762–2766Article dans une revue scientifiquetexte intégral -
Lenalidomide in combination with intravenous rituximab (revri) in relapsed/refractory primary cns lymphoma or primary intraocular lymphoma: a multicenter prospective "
Annals of Oncology, 04-2019, 30 (4), 621-628Article dans une revue scientifiquetexte intégral -
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health and Quality of Life Outcomes, BioMed Central, 15-11-2019, 17, 173Article dans une revue scientifiquetexte intégral